NGeneBio Co., Ltd. (KOSDAQ: A354200)
Health Care · Biotechnology · KR
₩1,694.00
-15.22% today · -68.3% 1Y
NGeneBio Co., Ltd. (KOSDAQ: A354200) operates in the Biotechnology industry within the Health Care sector. The company is valued at $10.92M.
Over the last twelve months the share price has lost 68.3%, trading between 1.44K and 8.29K.
Tweenvest scores NGeneBio Co., Ltd. across four factors: quality 17/100, value 56/100. Its strongest factor is value.
A354200 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.92M
- Revenue (TTM)
- $20.50M
- P/E
- —
- EPS
- -873.48
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- ₩8,295.00
- 52-week low
- ₩1,443.00
- Avg volume (3M)
- —
- Shares outstanding
- 8.94M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.